NEUROMICS

Panobinostat Data Sheet

Catalog Number:	MC11105	**Product Type:**	Small Molecule
Bio-Activity:	HDAC inhibitor	**CAS #:**	404950-80-7
Research Categories:	Epigenetics, cell death, cancer	**Chemical Name:**	(E)-N-Hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
Solubility:	Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 5 mg/ml with warming).	**Molecular Formula:**	C21H23N3O2
Purity:	> 98%	**Molecular Weight:**	349.44
Format:	Powder	**Ship Temp:**	Ambient
Storage:	-20°C		

Application Notes

Description/Data:
A potent inhibitor of class I and II HDACs [1]. Cotreatment with panobinostat and an HSP90 inhibitor caused synergistic apoptosis in human CML-BC and AML cells [2]. A potent antimyeloma agent that overcomes drug resistance [3].

References:

1) Geng et al. (2006), Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer; Cancer Res., 66 11298

2) George et al. (2005), Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3; Blood, 105 1768

3) Maiso et al. (2006), The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance; Cancer Res., 66 5781

FOR RESEARCH USE ONLY

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com